Tudor Investment Corp
CCCC icon

Tudor Investment Corp’s C4 Therapeutics CCCC Stock Holding History

Tudor Investment Corp’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,162
Closed -$46.9K – 2736
2024
Q2 		$46.9K Buy
+10,162
New +$60.6K ﹤0.01% 2230
2023
Q4 		– Sell
-15,223
Closed -$28.3K – 2404
2023
Q3 		$28.3K Buy
+15,223
New +$46.4K ﹤0.01% 2200
2023
Q2 		– Sell
-23,966
Closed -$75K – 2471
2023
Q1 		$75K Buy
+23,966
New +$141K ﹤0.01% 2274
2022
Q4 		– Sell
-24,134
Closed -$212K – 2428
2022
Q3 		$212K Buy
24,134
+14
+0.1% +$145 ﹤0.01% 2028
2022
Q2 		$182K Buy
+24,120
New +$212K ﹤0.01% 1846
2022
Q1 		– Sell
-21,283
Closed -$685K – 2071
2021
Q4 		$685K Buy
+21,283
New +$842K 0.01% 1250

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tudor Investment Corp's CCCC Position: Q3 2024 in Review

Tudor Investment Corp sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 10,162 shares — an estimated $46.9K sold.

Tudor Investment Corp first reported a position in CCCC in Q4 2021 and held it in 6 quarters. The position peaked at $685K in Q4 2021. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • Tudor Investment Corp reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Tudor Investment Corp sold 10,162 C4 Therapeutics shares in Q3 2024, an estimated $46.9K.
  • Tudor Investment Corp first reported a position in C4 Therapeutics in Q4 2021 and held it in 6 quarters.
  • Tudor Investment Corp's C4 Therapeutics position peaked at $685K in Q4 2021.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Tudor Investment Corp's 13F filing for Q3 2024, filed 14 Nov 2024.